- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05917847
Awake VDL Intubation With Dexmedetomidine, a Case Series (DexAwake) (DexAwake)
Awake VDL Intubation With Dexmedetomidine, a Case Series
Study Overview
Detailed Description
Early after the videolaryngoscope'(VDL) introduction in clinical practice, the awake videolaryngoscopic (A-VDL) intubation took place with and instead of the awake video-bronchoscopic (A- VBS) intubation. The awake intubation is a safe profile technique that was underused since the only instrumentation available was the fiberoptic bronchoscope (FOB) or more recently the video-bronchoscope (VBS). With the VDL diffusion, the awake intubation option has eventually turned into a more utilized procedure, with the potential to become a daily procedure. This was also due to dexmedetomidine (DEX) introduction in The Operating Room pharmacopeia.
The emergency use of rescue techniques after failed intubation throws the operator into the rare, but unwanted emergency "Front of Neck Access" (FONA) scenario, while a failed awake intubation brings (carry, get) the operator into the "patient not intubated but safely and spontaneously breathing" scenario, moving away from the events of hypoxic complications and death.
Several steps must be standardized in order to homogeneously apply an awake intubation protocol. First, the patients need to be clinically evaluated for difficult intubation predictors. Most of the articles about prediction only investigated the relationship between difficult intubation' predictors and direct laryngoscopy and they showed poor to moderate sensitivity and specificity (Toshiga Shiga, Vannucci) but, moving on VDL' world this relationship has changed as showed by Cortellazzi et al with an AUC for El Ganzouri Risk Index improving from 0.74 to 0.9 using DL and Glidescope respectively. In addition to these considerations, all the most recent Airway Management Guidelines has confirmed as unmissable the clinical evaluation of anthropometric and clinical DI predictors. (DAS) Along with measuring all the EGRI parameters, it is pivotal to examine any abnormality in the head, pharyngo-laryngeal, neck, spine, and abdominal anatomy. Previous neck irradiation, mass lesions, neck circumference, super-obesity, severe cervico-dorsal kyphosis, or past pharyngo-laryngeal surgery have to be considered and may not alter the EGRI score that is, incidentally, made -as the other predictors -for apparently normal patients (Shiga).
A department protocol is recommended (awake intubation guidelines) but a low threshold for enrollment can be used to shorten and standardize the execution times.
We retrospectively evaluated 24 patients (from January 2019 to June 2021). For descriptive purposes, there are five procedural "Times": T0, T1, T2, T3, T4 and T5. T 0 is the start of the dexmedetomidine charge dose and local oral-pharyngeal anesthetic. In T1, the GAG reflex check is performed. In T2 fentanyl or ketamine is delivered. In T3 the local anesthetic is nebulized on vocal cord and trachea, under videolaryngoscopic view. T4 is the tube passage through the vocal cords. T5 is the EtCo2 curve assessment. At the end outcomes were measured.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Brescia, Italy
- Spedali Civili
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Abnormality in the head, pharyngo-laryngeal, neck, spinal anatomy, super-obesity, El Ganzouri Risk Index > 6 or high risk for ab ingestis or hemorrhage (i.e.: tongue, pharynx-hypopharynx cancer lesions or arteriovenous malformations)
Exclusion Criteria:
- Interdental distance <1 cm
- Need for emergency airway stabilization.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The number of A-VDL success
Time Frame: from the starting of sedation to the end of the intubation procedure
|
This was defined as the ability to identify good or poor glottic view without rupture of sedation or change in Rass/Ramsay sedation level.
|
from the starting of sedation to the end of the intubation procedure
|
|
The number of A-VDL intubation successes
Time Frame: from the starting of sedation to the end of the intubation procedure
|
This was defined as the number of effective tube passages and airway stabilization.
|
from the starting of sedation to the end of the intubation procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of intubations allocated after A-VDL to VBS intubation.
Time Frame: from the starting of sedation to the end of the intubation procedure
|
Airway stabilization
|
from the starting of sedation to the end of the intubation procedure
|
|
The kind of drugs used and dosage
Time Frame: from the starting of sedation to the end of the intubation procedure
|
Type of drug and dosage
|
from the starting of sedation to the end of the intubation procedure
|
|
Level of sedation obtained
Time Frame: from the starting of sedation to the end of the intubation procedure
|
Rass/ Ramsay
|
from the starting of sedation to the end of the intubation procedure
|
|
Presence absence of memory of pain or discomfort during the procedure
Time Frame: from the starting of sedation to the end of the intubation procedure
|
Pain or discomfort remembered by the patient
|
from the starting of sedation to the end of the intubation procedure
|
|
Presence/absence of complications
Time Frame: from the starting of sedation to the end of the intubation procedure
|
procedure abandonment for reasons other than poor glottic visualization, desaturation above 90%, bradycardia above 40
|
from the starting of sedation to the end of the intubation procedure
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Minutes from the beginning of sedation until airway stabilization
Time Frame: from the starting of sedation to the end of the intubation procedure
|
Time in minutes
|
from the starting of sedation to the end of the intubation procedure
|
|
Cormack and Lehane score obtained
Time Frame: from the starting of sedation to the end of the intubation procedure
|
C&L
|
from the starting of sedation to the end of the intubation procedure
|
Collaborators and Investigators
Investigators
- Principal Investigator: Elena Cagnazzi, MD, Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- DA001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Awake Intubation
-
Kocaeli City HospitalNot yet recruitingVideolaryngoscopy | Awake Fiberoptic Nasal Intubation | Awake Endotracheal Intubation | Airway Management Assessment | Supraglottic Airway Device InsertionTurkey (Türkiye)
-
Zagazig UniversityCompletedAwake Fiberoptic IntubationEgypt
-
Zagazig UniversityCompletedAwake Fiberoptic IntubationEgypt
-
Hospira, now a wholly owned subsidiary of PfizerCompletedAwake Fiberoptic IntubationUnited States
-
The First Affiliated Hospital of Anhui Medical...CompletedAwake Tracheal IntubationChina
-
Johannes Gutenberg University MainzCompletedAwake Fiberoptic IntubationGermany
-
Wake Forest University Health SciencesTerminatedDifficult Intubation | Awake Endotracheal Intubation | Airway AnesthesiaUnited States
-
Tongji HospitalRecruitingRemimazolam | Awake Endotracheal IntubationChina
-
Kaohsiung Medical University Chung-Ho Memorial...UnknownAwake Fiberoptic Nasal IntubationTaiwan
-
University Hospital, CaenCompletedAirway Complication of Anesthesia | Intubation;Difficult | Awake IntubationFrance
Clinical Trials on Awake intubation
-
Hacettepe UniversityRecruitingAwake Endotracheal IntubationTurkey (Türkiye)
-
Kocaeli City HospitalNot yet recruitingVideolaryngoscopy | Awake Fiberoptic Nasal Intubation | Awake Endotracheal Intubation | Airway Management Assessment | Supraglottic Airway Device InsertionTurkey (Türkiye)
-
Tanta UniversityNot yet recruitingTrauma | Patient Satisfaction | Airway Morbidity
-
Fudan UniversityCompletedIntubation | Anesthesia | TracheaChina
-
Ain Shams UniversityCompletedPracticality, Efficacy, and Ease of Lignocaine Nebulization Compared to Traditional Upper Airway Block for Awake Nasal Fiberoptic IntubationEgypt
-
Università Politecnica delle MarcheUnknownDifficult Airway IntubationItaly
-
Robert LodderUniversity of KentuckyCompletedType 2 DiabetesUnited States, India
-
Emory UniversityCompletedHealth BehaviorUnited States
-
Beijing Neurosurgical InstituteBeijing Tiantan HospitalNot yet recruiting